Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control

PHASE3CompletedINTERVENTIONAL
Enrollment

568

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Type 2 Diabetes
Interventions
DRUG

Saxagliptin

5mg, oral tablet, once daily for 24 weeks

DRUG

Placebo

oral tablet, once daily for 24 weeks

Trial Locations (30)

Unknown

Research Site, Hefei

Research Site, Beijing

Research Site, Chongqing

Research Site, Fuzhou

Research Site, Guangzhou

Research Site, Shijiazhuang

Research Site, Changsha

Research Site, Nanjing

Research Site, Changchun

Research Site, Dalian

Research Site, Shenyang

Research Site, Shanghai

Research Site, Chengdu

Research Site, Hangzhou

Research Site, Tianjin

Research Site, Hyderabaad

Research Site, Bangalore

Research Site, Mangalore

Research Site, Mumbai

Research Site, Nagpur

Research Site, Pune

Research Site, Coimbatore

Research Site, Cebu City

Research Site, Makati City

Research Site, Manila

Research Site, Marikina City

Research Site, Quezon City

Research Site, Jeonju

Research Site, Daegu

Research Site, Seoul

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

AstraZeneca

INDUSTRY